Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the management of type 2 diabetes and, more recently, obesity. Mimicking the action of the naturally occurring incretin hormone GLP-1, they enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety. Although all GLP-1 agonists act on the same receptor, important differences exist in their structure, duration of action, efficacy, side-effect profiles, and approved indications. Understanding these distinctions can help clinicians individualize therapy for patients.
Differences in the precise effects of GLP-1 agonists stem from variations in their molecular backbone. Some are based on naturally occurring peptides from nonhuman sources, while others are modified versions of human GLP-1 designed to resist rapid enzymatic breakdown. These structural variations influence half-life, dosing frequency, and immunogenicity, with human-based designs generally producing fewer antibody responses 1–3.
Perhaps the most clinically relevant differences among GLP-1 agonists involve how long they act in the body. Shorter-acting formulations tend to target post-meal glucose spikes by strongly delaying gastric emptying. In contrast, longer-acting options provide more sustained receptor activation, which helps lower fasting glucose and glycosylated hemoglobin. Both daily and once-weekly injections are available, and more recently an oral option has been introduced for patients who prefer pills over injections 1,4,5.
All GLP-1 agonists lower blood glucose and typically reduce glycosylated hemoglobin by about 1% on average, though some agents show greater potency than others. Longer-acting formulations tend to achieve more robust improvements in both glucose control and weight loss compared to shorter-acting ones. Certain higher-dose versions have also been specifically approved for obesity management, with clinical trials demonstrating substantial benefits for weight reduction 6–9.
Cardiovascular protection has become a key consideration in diabetes management. Large outcome trials demonstrate that several long-acting GLP-1 agonists reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease or at high risk. Others, in contrast, have revealed rather neutral effects. These distinctions influence drug selection, particularly in patients with type 2 diabetes and coexisting cardiovascular conditions 10–12.
Gastrointestinal side effects such as nausea, vomiting, and diarrhea are common across these drugs, though they tend to diminish with continued use. Shorter-acting agents may cause more nausea related to gastric emptying, whereas longer-acting ones are often better tolerated over time. Pancreatitis risk has been raised as a concern but remains rare. Meanwhile, gallbladder disease and a theoretical risk of thyroid C-cell tumors, seen in animal studies, have also been noted 13–15.
Although GLP-1 receptor agonists share a common mechanism, their differences prevent them from being interchangeable—structural origin, dosing schedule, potency in glucose and weight reduction, cardiovascular benefit, and side-effect patterns distinguish one agent from another. Clinicians must tailor therapy to individual patient needs, balancing efficacy, safety, convenience, and long-term outcomes.
References
1. Collins, L. & Costello, R. A. Glucagon-Like Peptide-1 Receptor Agonists. in StatPearls (StatPearls Publishing, Treasure Island (FL), 2025).
2. Moon, M. J. et al. Structural and Molecular Conservation of Glucagon-Like Peptide-1 and Its Receptor Confers Selective Ligand-Receptor Interaction. Front Endocrinol (Lausanne) 3, 141 (2012). DOI: 10.3389/fendo.2012.00141
3. Mariam, Z. & Niazi, S. K. Glucagon-like peptide agonists: A prospective review. Endocrinology, Diabetes & Metabolism 7, e462 (2024). DOI: 10.1002/edm2.462
4. Alzahrani, A. M. et al. Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity. Integr Pharm Res Pract 14, 59–72 (2025). DOI: 10.2147/IPRP.S503501
5. Zheng, Z. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). DOI: 10.1038/s41392-024-01931-z
6. GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UK https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know.
7. GLP-1 Agonists. Cleveland Clinic https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists.
8. Moiz, A. et al. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. The American Journal of Medicine 138, 934–940 (2025). DOI: 10.1016/j.amjmed.2025.01.021
9. Yao, H. et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384, e076410 (2024). DOI: 10.1136/bmj-2023-076410
10. Rivera, F. B. et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. American Journal of Preventive Cardiology 18, 100679 (2024). DOI: 10.1016/j.ajpc.2024.100679
11. Marx, N., Husain, M., Lehrke, M., Verma, S. & Sattar, N. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Circulation 146, 1882–1894 (2022). DOI: 10.1161/CIRCULATIONAHA.122.059595
12. Badve, S. V. et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 13, 15–28 (2025). DOI: 10.1016/S2213-8587(24)00271-7
13. Manne-Goehler, J. & Franco, J. Side effects of GLP-1 receptor agonists. BMJ 390, r1606 (2025). DOI: 10.1136/bmj.r1606
14. Filippatos, T. D., Panagiotopoulou, T. V. & Elisaf, M. S. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud 11, 202–230 (2014). DOI: 10.1900/RDS.2014.11.202
15. ELS, L. C. GLP-1 diabetes and weight-loss drug side effects: Harvard Health https://www.health.harvard.edu/staying-healthy/glp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more (2024).